EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|November 7, 2014
Asymptomatic, Enlarging Plaque: Your Dx?
This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals. Which of the following statements is true?
Advertisement
This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals.
Which of the following statements is true?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
2
Building Clinician Confidence to Prescribe HIV PrEP in Primary Care
3
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
4
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
5